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Juvenile Dermatomyositis (JDM) is a systemic immune-mediated disease of childhood,
characterized by muscle weakness, and a typical skin rash. Other organ systems
and tissues such as the lungs, heart, and intestines can be involved, but may be
under-evaluated. The inflammatory process in JDM is characterized by an interferon
signature and infiltration of immune cells such as T cells and plasmacytoid dendritic
cells into the affected tissues. Vasculopathy due to loss and dysfunction of endothelial
cells as a result of the inflammation is thought to underlie the symptoms in most organs
and tissues. JDM is a heterogeneous disease, and several disease phenotypes, each
with a varying combination of affected tissues and organs, are linked to the presence of
myositis autoantibodies. These autoantibodies have therefore been extensively studied
as biomarkers for the disease phenotype and its associated prognosis. Next to identifying
the JDM phenotype, monitoring of disease activity and disease-inflicted damage not
only in muscle and skin, but also in other organs and tissues, is an important part of
clinical follow-up, as these are key determinants for the long-term outcomes of patients.
Various monitoring tools are currently available, among which clinical assessment,
histopathological investigation of muscle and skin biopsies, and laboratory testing of
blood for specific biomarkers. These investigations also give novel insights into the
underlying immunological processes that drive inflammation in JDM and suggest a strong
link between the interferon signature and vasculopathy. New tools are being developed
in the quest for minimally invasive, but sensitive and specific diagnostic methods that
correlate well with clinical symptoms or reflect local, low-grade inflammation. In this
Wienke et al. Biomarkers and Immunopathogenesis in JDM
review we will discuss the types of (extra)muscular tissue inflammation in JDM and their
relation to vasculopathic changes, critically assess the available diagnostic methods
including myositis autoantibodies and newly identified biomarkers, and reflect on the
immunopathogenic implications of identified markers.
Keywords: juvenile dermatomyositis, tissue inflammation, vasculopathy, disease monitoring, biomarkers,
interferon signature, autoantibodies, personalized medicine
INTRODUCTION
Juvenile Dermatomyositis (JDM) is a systemic immune-mediated
disease of childhood. It is the most common idiopathic
inflammatory myopathy in children, with an incidence of 2–
4/million/year (1). Although the exact etiology is still elusive,
both genetic and environmental factors are thought to play a role
in the development of the disease (2–5). JDM is characterized
by inflammation of skeletal muscles and skin, leading to muscle
weakness and a typical skin rash of the face and hands (heliotrope
rash and Gottron’s papules, respectively), which are also used as
classification criteria (6, 7). Next to the muscle and skin, other
organs can be affected. Vital organ involvement, especially of the
lungs, is still the major cause of death in JDM patients (8, 9).
Although rare, cardiac involvement and microangiopathy of the
intestine, brain and kidneys have been described (10). Thus,
rather than being confined to specific tissues, JDM is a truly
systemic disease, which can affect multiple organ systems.
Before the introduction of corticosteroids as a treatment
option, mortality and morbidity among JDM patients were
high, and long-term outcomes were not the primary focus.
Since then, mortality rates have dropped from over 30% to 2–
3% (11). With increasing survival, long-term outcomes become
an important concern of patients and physicians, as patients’
quality of life and societal participation depend on it. Long-term
outcomes are likely dependent on various factors such as disease
severity and activity, response to treatment and medication side
effects which together determine the cumulative organ and tissue
damage.
Especially low-grade inflammation and extramuscular
manifestations of the disease are difficult to investigate
in routine clinical care and may therefore be overlooked.
Unrecognized, local inflammation leading to tissue damage and
subsequent organ dysfunction may have serious consequences
for short-term and long-term outcomes. So far, reliable
assessment of disease activity and the type and extent of
tissue involvement has been rather challenging. Current
clinical tools for assessment of disease activity require active
collaboration of patients, which can be difficult for young, unwell
children. Detecting low-grade inflammation or differentiating
clinically between various causes of muscle impairment is
even more challenging. Hence, there is a great need for
minimally invasive, objective and reliable diagnostic tools
for the assessment and monitoring of (low-grade) disease
activity and related organ involvement. Optimally, such tools
could guide clinical decision making, facilitate individually
tailored treatment regimens, and reduce the risk of over- and
under-treatment.
In this review we will discuss the types of (extra)muscular
tissue involvement that have been described in JDM and
their relation to vasculopathic changes, critically assess the
available diagnostic and monitoring tools and reflect on the
immunopathogenic implications of identified markers.
SIGNS OF SYSTEMIC DISEASE ACTIVITY
IN JDM BASED ON AFFECTED TISSUES
AND ORGANS
JDM patients can present with a spectrum of symptoms.
Most, but not all patients, have the classic combination of
muscle involvement and typical skin rashes. Approximately 1–
5% of JDM patients present with amyopathic JDM, but it was
estimated that 26% of these patients will eventually progress
to classical JDM, which can occur up to years after onset
(12). This indicates that the phenotype can evolve over the
course of the disease, possibly also dependent on treatment.
True amyopathic JDM however is very rare and mild muscle
involvement may be present but missed (13). Amyopathic JDM
generally has a relatively mild disease course with fewer systemic
manifestations, less required immunosuppressive treatment and
a good prognosis (12, 14, 15).
(Sub)Cutaneous and Other Extramuscular
Symptoms
Cutaneous symptoms can range from the pathognomonic
heliotrope rash and Gottron’s papules, to photosensitive rashes
such as malar and truncal erythema, and severe complications
such as skin ulceration and dystrophic calcinosis. Calcinosis
occurs in 12–47% of patients and can occur in the skin and in
subcutaneous, myofascial, or muscle tissue. Most often it is a
long-term complication and its presence has been associated with
delayed diagnosis andmore severe disease with poorer functional
outcomes. Effective treatment of calcinosis is still challenging,
but aggressive high-dose immunosuppression or, in very severe
cases, autologous stem cell transplantation have been shown to
be able to reverse calcinosis, suggesting that chronic (low-grade)
inflammation may be accountable for calcifications (16–20).
Cutaneous and oral ulceration affects up to 30% of patients and
is thought to result from occlusive endartheropathy of the small
vessels (10, 21). Lipodystrophy affects 8–14% of JDMpatients and
is often associated with hormonal andmetabolic changes (10, 22–
24). We suspect that patients with lipodystrophy may therefore
have an increased risk of cardiovascular events in the long-term.
Limb edema and arthritis are also common, occurring in 11–32
and 23–58% of patients, respectively (10).
Frontiers in Immunology | www.frontiersin.org 2 December 2018 | Volume 9 | Article 2951
Wienke et al. Biomarkers and Immunopathogenesis in JDM
Next to the skin and musculoskeletal system, other organ
systems can be involved, of which the lung is the most
frequently affected. Up to 75% of children with JDM develop
respiratory involvement, which may result from a complication
of respiratory muscle weakness or immunosuppressive therapy,
or from interstitial lung disease (ILD) (25, 26). ILD occurs in
8–19% of juvenile myositis patients and has been described as
the major cause of death in JDM (27–30). Cardiac involvement
may be present subclinically more often than recognized, as
even in JDM patients without clinical cardiac dysfunction
abnormal ECG and echocardiographic findings are relatively
common (31–33). Conduction abnormalities and myocarditis
have been reported, and systolic and diastolic dysfunction was
found after long-term follow-up (34–37). Cardiac complications
are thought to result from myocarditis and coronary artery
disease as well as involvement of the small vessels of the
myocardium (38). Involvement of the gut or neural system are
rare complications of JDM and are also thought to result from
an underlying small vessel angiopathy or vasculitis (39–41).
Intestinal consequences of the small vessel angiopathy include
ulceration, perforation, hemorrhage, pneumatosis intestinalis
and malabsorption (42–44).
Vasculopathy
The pathologic changes underlying symptoms and tissue damage
in the skin, muscles, and vital organs have a common factor: in
all the affected tissues typical vasculopathic changes are observed,
which include loss of capillaries (capillary dropout), perivascular
inflammation, and (occlusive) small vessel angiopathy (21, 45).
In a recently reported French JDM cohort of 116 patients,
vasculopathy-related complications were the main cause of
admission to the intensive care unit, illustrating the severity
and relevance of vascular involvement in JDM (46). These
complications include life-threatening disorders like systemic
capillary leak syndrome, recently also described in 3 patients with
JDM (47).
Deposition of complement, immune complexes and anti-
endothelial antibodies is thought to play an important role in
endothelial damage and subsequent capillary dropout (48–54).
Clinically, the severity of vasculopathy and the disease phenotype
have also been linked. The presence of prominent vascular injury
in muscle biopsies identified a subgroup of patients with more
severe clinical presentation and outcomes, including profound
muscle weakness, limb edema and gastrointestinal involvement
(55). This suggests that local vasculopathic changes can reflect
systemic vasculopathy and the resulting clinical symptoms.
Nailfold capillaroscopy, a commonly and easily used indicator of
disease activity in clinical practice, is also based on this principle.
The pathologic changes observed in nailfold capillaries, such
as capillary dropout, branching and dilatation, likely reflect the
systemic blood vessel abnormalities. Loss of end row nailfold
capillaries is significantly associated with clinical disease activity
scores for muscle and skin and can thus be used as a marker
of skin and muscle activity. Nailfold capillaroscopy is especially
suited as a non-invasive tool to follow up changes in disease
activity over time in patients (56–59).
Taken together, JDM is a truly systemic disease in which not
only the muscles and skin are affected, but also vital organs can
be involved. The presence of typical vasculopathic changes in the
various affected tissues points toward a central role for systemic
endothelial dysfunction in the pathogenesis of JDM.
MONITORING OF DISEASE ACTIVITY AND
TISSUE INVOLVEMENT
During clinical follow-up, monitoring of disease activity is crucial
to determine the rate of medication tapering or to assess the
requirement for intensification of immunosuppressive therapy.
Next to clinical evaluation, various tools have been investigated
for monitoring of disease activity, among which autoantibodies
and other circulating biomarkers, and histopathologic evaluation
of muscle biopsies, as well as several imaging techniques.
Clinical Assessment
The primary and most important evaluation of disease activity
involves clinical assessment by experienced clinicians and health
care professionals. Over the past years, several scoring tools
have been devised for internationally standardized evaluation
of disease activity (60). The most commonly used tools are
now the childhood myositis assessment scale (CMAS), manual
muscle testing of 8 muscle groups (MMT-8), physician’s and
patient’s global assessment on a visual analog scale (PGA),
cutaneous assessment tool (CAT), cutaneous dermatomyositis
disease area and severity index (CDASI), disease activity score
(DAS), myositis disease activity assessment tool (MDAAT) and
childhood health assessment questionnaire (CHAQ) (61–69).
Combined scoring systems are currently being developed (70).
The Pediatric Rheumatology International Trials Organization
(PRINTO) has composed criteria for defining clinically inactive
disease (71). A recent re-evaluation of these PRINTO criteria
showed that skin disease may be underestimated as a factor in
the assessment of disease activity (72).
Clinical measures of disease activity, however, have limited
capacity to detect low-grade inflammation in the tissues which
does not cause overt symptoms, but may still contribute to
tissue damage in the long term. Moreover, it is challenging to
differentiate between various underlying causes of symptoms by
clinical assessment. For example, muscle weakness may result
from an ongoing inflammatory process, from medication side
effects (e.g., steroid myopathy), muscle damage or effects of
immobility. Biological assessment of the affected tissues and
organs can therefore be helpful or even necessary to aid clinical
decision-making concerning medication dose and additional
interventions.
Biomarkers for Disease Course, Activity,
and Tissue Involvement
Laboratory investigation of blood is a minimally invasive and
time-efficient procedure, especially compared to muscle biopsy
and some of the imaging methods. It is therefore particularly
suited as a method for serial sampling during clinical follow-
up. Laboratory investigation can be used for measurement of
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autoantibodies and for biomarkers related to disease activity and
specific (extra)muscular symptoms.
Autoantibodies
Antibodies found in myositis include myositis-specific
autoantibodies (MSA), relatively specific to myositis, and
myositis-associated antibodies (MAA), which are observed
both in myositis and other connective tissue diseases (6). In the
past years, different disease phenotypes have been linked to the
presence of autoantibodies and particularly myositis-specific
autoantibodies (16). The frequencies of autoantibodies in
juvenile patients differ substantially from adult DM patients (73).
Anti-TIF1 (p155/140) and anti-NXP2 (p140 or MJ) are the most
commonly identified autoantibodies in Caucasian JDM patients
(20–35 and 16–23%, respectively) (28, 73–76). Anti-TIF1 is
associated with skin ulceration, photosensitive skin rashes,
lipodystrophy, and edema (24, 75–78), whereas anti-NXP2 is
associated with a severe disease course with more profound
muscle involvement, calcinosis, gastrointestinal ulceration, joint
contractures, and dysphonia (75, 77, 79, 80). A recently identified
myositis specific autoantibody which is especially frequent in
the Asian JDM population, is anti-MDA5 (CADM-140) (81).
It is found in 33% of Asian JDM patients, compared to 7%
of Caucasian patients (8, 82). Patients with anti-MDA5 have
a higher risk of developing ILD than patients without these
antibodies. This anti-MDA5 conferred risk is seen in both
Asian and Caucasian JDM cohorts, although the risk difference
appears to be more pronounced in Asian cohorts (8, 83).
Common symptoms in Caucasian patients with anti-MDA5
antibodies include oral and cutaneous ulceration, arthritis, and
milder muscle disease with fewer histologic abnormalities and a
higher remission rate off medication after 2 years of follow-up
(76, 82, 84, 85). Less frequently identified autoantibodies in
the juvenile population include anti-Mi2 (4–10%) and anti-
amino-acyl-tRNA synthetase antibodies such as anti-Jo-1 (1–3%)
and anti-SAE (<1%). Anti-SRP and anti-HMG-CoA-reductase
(Anti-HMGCR) autoantibodies, both accounting for <3% of
juvenile myositis patients, are associated with a necrotizing type
of myopathy with severe muscle weakness (73, 76, 86, 87).
It remains unclear whether each MSA reflects a distinct
pathologic process, influencing the type and severity of disease
phenotype and tissue involvement. Notably, autoantibodies
against Jo-1, TIF1, SRP, and Mi-2 are not only informative at
disease onset, but their levels have been found to correlate with
disease activity during follow-up in the context of rituximab
treatment (88). This highlights that perhaps autoantibodies
should be measured during or soon after the first clinic visit as
their levels may decline and become undetectable in remission.
A last and different (not myositis-specific) category of
autoantibodies identified in JDM comprises autoantibodies
against components of endothelial cells, which are thought
to contribute to capillary loss. These anti-endothelial cell
autoantibodies (AECA) were detected in 76% of JDM patients, as
opposed to 30% of control patients (49). Twenty-two candidate
target autoantigens for AECA were identified in JDM plasma, 17
of which were proteins associated with antigen processing and
protein trafficking (50). Identification of autoantibody targets
may provide novel insights into the auto-immune process and
self-antigens involved in JDM.
Biomarkers for Systemic Inflammation and Muscle
Disease Activity
Reliable assessment of disease activity during follow-up can
be aided by laboratory markers that represent systemic and/or
local inflammation. Especially for detection of low-grade
inflammation and for differentiation between various causes of
muscle weakness, laboratory investigation can be a helpful or
even necessary tool.
So far, reliable and validated laboratory markers for disease
activity and tissue involvement in JDM are still lacking. A
large number of proteins in plasma, serum, and urine as
well as circulating immune cell subsets have been investigated
as potential biomarkers for (tissue-specific) disease activity in
patients with JDM (Tables 1, 2). In theory, every biological
parameter that can be measured, could serve as a biomarker.
To be suited for use in clinical practice however, a biomarker
has to meet additional criteria, such as being reliable, robust,
relatively stable and easy to measure. In the following paragraphs
we highlight all biological markers that have been associated with
disease activity in JDM, regardless of their suitability for use in
clinical practice, as some of these identified markers may still
contribute to the understanding of the immunopathogenesis of
JDM. However, it is important to note that due to the rarity of the
disease, many of these studies were carried out in small cohorts of
<30 patients (as outlined in Tables 1, 2). Insights based on such
small numbers have limitations in a heterogeneous disease like
JDM. Therefore, validation of identifiedmarkers in larger cohorts
is crucial before implementation into clinical practice.
Currently used laboratory markers
The markers that are currently used in clinical practice, AST,
ALT, LDH, aldolase and in particular creatine kinase activity
(CK), do not correlate as well with disease activity in JDM as in
DM (125–127). At diagnosis, any one muscle enzyme was only
elevated in 80–86% of patients with JDM and CK was found
to be elevated in only 61–64% of patients (125, 128). In almost
20% of patients the most abnormal measurement of CK was
not elevated above normal values (28). Low muscle enzymes at
first presentation may be associated with delayed diagnosis (129).
During follow-up, CK may underestimate disease activity due
to suppressed release by corticosteroids, circulating inhibitors of
CK activity, or loss of muscle mass (127, 130–132). On the other
hand, CK and aldolase can be elevated in steroid myopathy and
are therefore not reliable as markers for disease activity requiring
more potent immunosuppression (133). However, according
to recent consensus guidelines, these muscle enzymes are still
regarded as an important monitoring tool (134, 135).
Markers related to the interferon signature
An important group of investigated biomarkers is related to the
type 1 interferon (IFN) signature, which has been demonstrated
in the peripheral blood and muscle biopsies of JDM patients
(136, 137). Activated plasmacytoid dendritic cells (pDC) are
generally thought to be the main producers of the type 1 IFNs
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(IFNα and IFNβ) in JDM. This notion may be challenged
by a recent study measuring circulating IFNα with a highly
sensitive assay and investigating the cellular source of IFNα
in several systemic inflammatory diseases. JDM patients had
higher levels of circulating IFNα than patients with systemic
lupus erythematosus (SLE), but lower levels than patients
with monogenic interferonopathies. However, neither isolated
circulating pDC nor other circulating immune cell subsets from
JDM patients expressed more IFNα than cells from healthy
controls, suggesting that a non-circulating cellular source may be
responsible for IFNα production in JDM (138).
Due to the lack of available methods to measure circulating
IFNα and IFNβ until recently, the type 1 IFN signature,
consisting of genes upregulated in response to IFNα or IFNβ
stimulation, was used as a surrogate marker of type 1 IFN
levels. The type 1 IFN signature in whole blood of three mixed
DM and JDM cohorts correlated weakly to moderately with
global disease activity [spearman r (rs) = 0.33–0.44] and muscle
activity (rs = 0.44–0.47), while single IFN signature related
serum chemokinesMCP-1, IP-10 (CXCL10) and ITAC (CXCL11)
had moderate to strong correlations with global (rs = 0.42–
0.66), muscle (rs = 0.44–0.50), and extraskeletal disease activity
(rs = 0.42–0.55) (115–117). MxA expression in PBMC, also used
as a surrogate for the IFN signature, had a very strong correlation
with muscle disease activity of JDM patients (rs = 0.80) at
disease onset, but not with skin disease activity (89). IFNα activity
measured by a functional reporter assay was also higher in JDM
patients than controls (90).
Recently, IP-10, TNF receptor 2 (TNFR2) and galectin-9 were
found to strongly correlate with global disease activity (r = 0.60–
0.75) in two studies by Enders et al. (93, 94) IP-10, together with
MCP-1 and eotaxin, was also higher in 54 JDM patients a median
of 17 years after disease onset thanmatched healthy controls (92).
TNFR2 correlated with CK in a mixed IIM cohort (rs = 0.55)
(118). Galectin-9 was recently identified as a biomarker for the
IFN signature in SLE and anti-phospholipid syndrome (139).
IP-10, TNFR2 and galectin-9 are promising biomarkers for
disease activity, as they can potently discriminate between active
disease and remission even during treatment (93, 94). After stem
cell transplantation and concomitant eradication of circulating
immune cells, their levels stayed high over several months,
which suggests that these proteins are not primarily produced by
circulating immune cells, but rather by non-circulating immune
or tissue cells, just as IFNα (94, 138). IP-10 and galectin-9 are
currently being validated as biomarkers for disease activity in two
large international JDM cohorts.
One of the best investigated biomarkers so far in JDM is
neopterin, a catabolic product of guanosine triphosphate, which
was previously shown to be a marker of immune activation that
can be induced by stimulation with IFNγ (140). In the first study
identifying serum neopterin as a biomarker for JDM, neopterin
levels correlated strongly with muscle strength impairment in
15 JDM patients (rs = 0.68) (96). Elevated serum neopterin
levels at diagnosis compared to remission were confirmed in
an independent cohort (95). In a juvenile myositis validation
cohort, plasma neopterin (n= 13), and quinolonic acid (n= 24),
however, did not correlate withmyositis disease activity measures
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(97). Urine neopterin (n = 45) moderately correlated with
global (rs = 0.42), muscle (rs = 0.50–0.62) and skin activity
(rs = 0.49), and edema on MRI (rs = 0.55). Urine quinolonic
acid also correlated with global and muscle activity and edema
on MRI (rs = 0.45–0.61) (97). Despite these efforts of validation,
neopterin has not been widely implemented into clinical practice
as a biomarker for disease activity in JDM.
Other inflammatory mediators
Next to type 1 IFN-related markers, other inflammatory
mediators have been studied as biomarkers for JDM. The
innate TLR4 ligand myeloid related protein 8/14 (MRP8/14
or S100A8/9), originally found to be elevated in patients with
systemic-onset juvenile idiopathic arthritis (JIA), correlated
moderately to strongly with global and muscle disease activity
in a large cohort of 56 JDM patients (rs = 0.55–0.65) (98, 141).
Another marker adopted from studies in JIA, the soluble IL-2
receptor, was elevated at disease onset compared to remission
(95, 142). Serum/plasma levels of the more conventional pro-
inflammatory cytokines IL-6, IL-8, and TNFα also moderately
correlated with global (rs = 0.19–0.46) and muscle disease
activity (rs = 0.35–0.52) in three mixed JDM and DM
cohorts (116, 117). Remarkably, CRP levels did not increase
during disease flares (99). BAFF and especially its antagonistic
non-cleavable form 1BAFF, both important for survival and
maturation of B cells, moderately correlated with global, muscle
and extraskeletal VAS (rs = 0.27–0.54), and CK (rs = 0.37) in two
mixed IIM cohorts (119, 120).
Markers related to vasculopathy and cardiovascular risk
Due to the vasculopathic component of JDM, markers related
to endothelial activation and dysfunction were explored for
their association with disease activity. Von Willebrand factor
(vWF) was increased during most periods of active disease
in a prospective cohort study, but did not reliably predict
disease flares in another study (107, 108). sICAM-1, a marker
of endothelial activation, was higher during active disease than
remission in a combined cohort of juvenile patients with
various systemic autoimmune diseases. VCAM-1, sICAM-3,
and L-selectin did not correlate with disease activity, although
expression of MiRNA-10a in JDM muscle, which is negatively
associated with VCAM-1 expression, showed a correlative trend
with muscle and global DAS [Pearson r (rp) = −0.45] (110,
123, 124). C3d and fibrinopeptide A, which are related to
vasculopathic changes, were higher in JDM patients with active
disease than in remission (109). Endothelial progenitor cell
numbers did not differ between JDM patients and controls and
did not correlate with disease activity (111).
In view of the increased cardiovascular risk in JDM patients,
the lipid profile has been investigated in relation to disease
activity (41). Serum HDL negatively correlated with muscle
activity (rs = −0.54), but not global or skin activity (112).
Triglyceride levels correlated strongly with global disease activity
assessed by DAS (rs = 0.61) and LDL was higher in patients with
a higher disease activity (113). Gene expression of the adipokine
resistin in PBMCwas also upregulated in JDMpatients compared
to controls and moderately correlated with global and muscle
disease activity (rs = 0.51 and rs = 0.50, respectively) (114).
These results indicate that the cardiovascular risk profile is more
pronounced in JDM patients with active disease.
Circulating immune cell subsets as biomarkers for disease
activity
Among the circulating immune cell subsets, T cells and B cells
have been studied most extensively in relation to disease activity
in JDM. In two mixed cohorts of JDM and DM patients, the
frequency of T cells, and especially CD8+ and IFNγ-producing
T cells, was decreased during active disease, while the frequency
of B cells and IL-4 producing CD4+ T cells was increased
compared to remission (121, 122). This may suggest a shifted
balance toward a T helper 2 (Th2) type immune response. In
cohorts with only JDM patients, total B cell numbers were also
increased compared to controls and changes in B cell frequencies
accompanied changes in disease activity (rs = 0.47) (100, 106).
Within the B cell compartment, numbers and frequencies of
circulating immature transitional B cells correlated strongly
with global disease activity (rs = 0.69–0.71). Compared to
healthy pediatric controls, these specialized B cells were highly
proliferative, had a prominent IFN signature and produced less
of their regulatory signature cytokine IL-10 (106). Plasmablast
frequencies were also increased during active disease compared
to remission (102).
Several T cell subsets have been studied in JDM. In 26 new-
onset JDM patients the blood gene expression of Th17-related
genes, such as RORC and IL-17F, Th1-related genes, including
STAT4, and Th2-related genes, including GATA3 and STAT6,
was studied in relation to disease activity. RORC, IL-17F, STAT4,
and GATA3 positively correlated with muscle activity and RORC
and STAT4 correlated with global activity. This would suggest
that the immune response is not specifically skewed toward a
certain T helper response. However, at baseline, JDM patients
had higher gene expression of Th17 related cytokines IL-23, IL-
17F, IL-6, and IL-21 than DM patients, indicating that the Th17
pathway may play a more prominent role in the pathogenesis
of JDM than DM. Changes in BCL6, a transcription factor for
follicular helper T cells, correlated negatively with a change in
extramuscular activity (105). Within CXCR5+ follicular helper
T cells, the Th1 subset was decreased in active JDM compared to
remission and controls, and Th2 and Th17 subsets were increased
in JDM compared to controls (102). Regulatory T cell frequencies
in muscle biopsies did not correlate with muscle activity, but
suppressive activity of circulating Tregs may be impaired during
active disease (104). Finally, global disease activity correlated
moderately with the activation status of circulating T cells
assessed by CD69 expression (rs = 0.43), but not with CD25 and
HLA-DR expression (100, 103). The expansion and functional
alteration of particular B cell and CD4+ T cell subsets, coinciding
with changes in disease activity, hints toward the involvement of
these cell subsets in the pathogenesis of JDM.
In conclusion, many circulating, either soluble or cellular,
markers have been studied for their relation with muscle and
global disease activity. Correlations with disease activity were
only moderate for most markers, and some of these molecules
are relatively unstable in blood samples or complicated to
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measure, rendering them unsuited for use in clinical practice. The
highest correlations with disease activity were found for markers
related to the IFN signature, the lipid profile, for MRP8/14, and
immature transitional B cells. However, most of these biomarkers
were identified in small patient cohorts and except for neopterin,
so far none have been reproduced or thoroughly validated in
independent and large JDM cohorts. Neopterin was investigated
in a validation cohort, but its correlation with disease activity
could only be confirmed in urine, not in plasma. Galectin-9 and
IP-10 are currently being validated in two international cohorts
and are promising biomarkers for implementation in clinical
practice due to their high sensitivity and stability in serum.
Biomarkers for Extramuscular Disease Activity
Next to markers for global and muscle disease activity,
biomarkers for involvement of specific tissues and organs have
been investigated. Four studies by Kobayashi et al. have focused
on biomarkers for ILD, and specifically the rapid progressive
(RP-ILD) and chronic ILD type, in a Japanese JDM cohort.
Not only the presence, but also the level of anti-MDA5 was a
sensitive and specific marker for ILD, with the highest levels
found in patients with RP-ILD (8, 143, 144). In addition, BAFF,
APRIL, KL-6, and IL-18 levels were higher in patients with RP-
ILD compared to chronic ILD and JDM patients without ILD
(145). KL-6 was prognostic for ILD, as it stayed high in patients
with persistent damage on HRCT (144). Biomarkers for cardiac
involvement were tested in a Norwegian JDM cohort, a median
of 17 years after diagnosis. Eotaxin and MCP-1 were elevated
in patients with cardiac dysfunction and correlated moderately
to strongly with systolic and diastolic dysfunction especially in
patients with persistently active disease (rs = 0.45–0.65) (146).
In the same cohort, a reduced heart rate variability, which is
an indicator of cardiac disease, correlated moderately with ESR,
hsCRP, and also MCP-1 and eotaxin levels (rs = 0.29–0.47) (147).
Next to the autoantibody NXP2, which is prognostic for the
development of calcinosis, phosphorylated matrix Gla protein
was shown to be higher in patients with calcinosis than without
calcinosis (79, 148). Reduced osteocalcin levels were found to be
predictive of reduced bone mass, even before start of steroids
(149). The presence of the TNFα-308A allele is associated with
a more severe disease in JDM. However, apparent associations
with this allele are likely to reflect the association with ancestral
haplotype 8.1 due to linkage disequilibrium and should be
interpreted with this in mind (150). Patients with this genotype
are reported to show prolonged symptoms requiring≥36months
of immunosuppressive therapy, a higher incidence of pathologic
calcifications, increased production of TNFα by peripheral blood
mononuclear cells in vitro and JDM muscle fibers in vivo, a
higher IFNα activity and a higher rate of complications arising
from occlusion of capillaries. Vascular occlusion has been linked
to higher levels of the anti-angiogenic thrombospondin-1 (90,
151–154). In summary, a number of potential biomarkers for
extramuscular disease activity has been identified, and especially
for ILD and cardiac dysfunction the biomarkers seem promising.
Validation in independent cohorts will have to confirm their
potential as biomarkers for these extramuscular symptoms.
Histopathology of Muscle and Skin
Biopsies
The diagnostic criteria for JDM by Peter and Bohan encompass
histopathological findings consistent with DM: “necrosis of
myofibers, phagocytosis, regeneration with basophils, large
vesicular sarcolemmal nuclei, and prominent nucleoli, atrophy
in a perifascicular distribution, variation in fiber size and an
inflammatory exudate, often perivascular” (155, 156). For a long
time, muscle biopsies were therefore taken as part of routine
diagnostic workup. However, with evolving diagnostic options
and more specialized trained pediatric rheumatologists muscle
biopsies are currently not always considered a necessity for
diagnosis (135).
One of the main problems hindering standardized evaluation
of muscle biopsies was the lack of an internationally agreed
upon scoring tool. An international consensus group of pediatric
rheumatologists and pathologists developed such a tool, which
encompasses 4 histopathological scoring domains: inflammatory,
vascular, muscle fiber and connective tissue changes (157). The
scoring tool has now been validated in an independent cohort
consisting of 55 patients and was found to correlate with clinical
measures of disease activity, including CMAS, PGA, and MMT-
8 (rs = 0.40–0.62) (45). Muscle biopsy scores may also have
prognostic potential: in combination with MSA group, these
scores were found to predict the risk of remaining on treatment
over time, based on analysis of muscle biopsies from 101 JDM
patients (158).
The most common findings in muscle biopsy specimens
in JDM compared to healthy individuals or patients with
non-inflammatory muscle diseases, are profound upregulation
of MHC I expression on muscle fibers, increased expression
of integrins and complement and membrane attack complex
deposition on capillaries and perimysial large vessels, a type 1 IFN
signature and immune cell infiltrates consisting mostly of mature
pDC, memory CD4+ T cells, and B cells (48, 52, 159–169).
(Figure 1) The IFN signature, measured by expression of MxA,
correlated with muscle disease activity (166). In skin biopsies
similar features are found, with the additional presence of diffuse
mast cell infiltration (164).
Several studies have suggested associations between
histopathological findings in muscle biopsies and disease
duration before the biopsy or disease severity at a later time
point. Biopsy specimens taken after a short duration of untreated
disease (<2 months), showed higher expression of VCAM-1
(which correlated with higher serum soluble VCAM-1) and
expression of genes involved in stress response and protein
turnover, whereas biopsies taken after more than 2 months of
untreated disease hadmore pDC infiltration, higher expression of
genes involved in the immune response and vascular remodeling
and more apoptosis-related markers (171–173). Thus, it should
be taken into account that histological findings can depend on
the disease duration before the biopsy. In addition, these findings
may indicate that endothelial activation is an early feature of
JDM, which precedes immune cell infiltration and vasculopathy.
The degree of vasculopathy and vascular injury (as defined by
marked capillary dropout, increased direct immunofluorescent
arterial staining and lymphocytic vasculitis, amongst others)
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FIGURE 1 | Histopathological features and biomarkers in JDM. JDM is characterized by vasculopathic changes in the tissues, with loss and dysfunction of endothelial
cells, leading to capillary dropout and subsequent atrophy of muscle fibers. The exact chain of events leading to loss of blood vessels and muscle fibers is not known,
but it is thought that both overexpression of MHC-I (and MHC-II) on myocytes and endothelial damage are early events in the cascade (159, 170). They result in the
first attraction of immune cells to the tissue, probably by a stress response of the myocytes and endothelial cells, leading to a first production of chemoattractants. The
immune cell infiltrates, which can be organized in lymphoid structures, consist mostly of CD4+ and CD8+ memory T cells, B cells, mature plasmacytoid dendritic cells
(pDC) and monocytes. CD4+ and CD8+ T cells are considered responsible for direct killing of muscle cells. pDC are considered the main producers of type I
interferons (IFNs), which explains the IFN-I signature that is found in the muscles of JDM patients. Some typical IFN-inducible chemokines, CXCL9 (MIG), CXCL10
(IP-10), and CXCL11 (ITAC), are known for their angiostatic properties. The receptor for these cytokines, CXCR3, is upregulated on endothelial cells in JDM muscle,
which may be one of the factors contributing to endothelial dysfunction (137). Other factors include anti-endothelial circulating antibodies (AECA), complement and
membrane attack complex (MAC) deposition on endothelial cells. Endothelial cells in muscle also express high levels of ICAM-1 and VCAM-1, which further enables
extravasation of immune cells into the tissues and promotes a positive feedback loop resulting in further tissue damage. Not only immune cells in the tissues, but also
circulating immune cells show a type I IFN signature and increased IFNα activity. Various circulating markers reflecting immune activation and endothelial activation or
distress are increased during active disease in JDM and can potentially be used as biomarkers for disease activity.
was associated with a more severe and chronic disease, with
severe or persistent weakness, low remission rates at 12
months requiring additional treatment, subcutaneous edema,
and chronic ulcerative disease of the skin and gastrointestinal
tract (21, 55, 165). The degree of vasculopathy was also correlated
with the expression of angiostatic chemokines MIG, IP-10 and
ITAC (137). This indicates that the degree of vascular injury
may be one of the most important factors determining long-term
disease outcomes and that it is related to the IFN signature.
Not only the type of immune cell infiltration, but also the
organization of immune cells in the muscle is of significance
in JDM. Organization of immune infiltrates in lymphocytic
aggregates or lymphoid follicle–like structures with dendritic
cells and T cells, as compared to diffuse infiltrates, was associated
with a more severe disease course and less response to treatment
(174). MHC I expression, one of the most prominent and early
histological features in JDM, did not correlate with clinical
features of the disease (159, 160, 175).
The importance of thorough and standardized assessment of
tissue involvement is underlined by the fact that even in cases
with amyopathic DM, with normal EMG and MRI findings,
the muscle biopsy can show focal endomysial lymphocyte
and macrophage aggregates and 90% positivity for HLA class
I in the sarcolemma (176). Unrecognized, low-grade muscle
inflammation may be undertreated, resulting in a larger risk
of long term damage. However, muscle biopsy is not routinely
performed for children with JDM in all centers and therefore in
future, biomarkers which are measureable in blood and correlate
with biopsy features would represent a major advance.
IMMUNOPATHOGENIC IMPLICATIONS:
INTERFERONS AND VASCULOPATHY
From the biological research conducted in JDM so far, it has
become clear that IFNs and their signature play an important
role in the immunopathogenesis of JDM (Figure 1). The IFN
signature is detectable in muscle fibers, myogenic precursor
cells, endothelial cells, skin and several circulating cell subsets of
patients with JDM and could point toward a viral etiology (89,
106, 167). Although it has never been demonstrated definitively,
several studies suggest that infections may be more common
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before onset of JDM (177–180). Not only are IFNs potent
drivers of (auto)inflammation, they may also be anti-angiogenic
factors that could directly or indirectly contribute to endothelial
damage and loss in JDM: directly by inhibiting angiogenesis and
disrupting the vascular network organization and indirectly by
inducing several other angiostatic factors such as galectin-9, IP-
10, and ITAC (137, 181–186). In addition, type 1 IFNs inhibit
the generation of myotubes and induce atrophy-associated genes
in differentiated myotubes. Human skeletal muscle cells can also
produce large quantities of IP-10 upon stimulation with IFNγ
and TNFα (186, 187).
Rather than being produced by circulating immune cells, IFNs
are probably mainly produced within inflamed tissues. Satellite
cells, active myogenic cells and endothelial cells in JDM muscle
strongly express IFNβ (167). The notion that non-circulating
cells within tissues are responsible for IFN production also
fits observations by Rodero et al. (138). In particular within
muscle of JDM patients the dysbalance between angiogenic and
angiostatic factors can contribute to endothelial loss (137, 188).
Endothelial cells in JDM muscle downregulate genes related
to vessel development, cell adhesion and migration, which are
essential for angiogenesis (167). Downregulation of these genes
is likely a key event in the development of vasculopathy. Next
to being a target of the inflammation, the endothelium may also
play an active role in the inflammatory process. In biopsies from
JDM patients endothelial cells express inflammatory features,
such as high levels of adhesion molecules ICAM-1 and VCAM-
1, and produce cytokines and chemokines (161). These can
facilitate the attraction and invasion of immune cells into tissues,
thereby supporting the inflammatory process and subsequent
damage. IP-10 and ITAC were the most highly upregulated genes
in endothelial cells from JDM muscle and correlated with the
degree of vasculopathy (137, 167). Endothelium-derived IP-10
can even stabilize the interaction between T cells and endothelial
cells, thereby possibly contributing to the chronicity of T cell
infiltration (189). Recently, a new function has been ascribed to
endothelial cells as “semi-professional” antigen presenting cells,
which act as sentinels for antigens, and possibly self-antigens, in
tissues and facilitate T cell trafficking into these tissues (190, 191).
The high expression of MHC molecules on endothelial cells in
JDMmuscle may support the notion that this process is involved
in JDM (160, 175). Although the exact mechanisms of interaction
between immune cells and endothelial cells in JDM are still
elusive, they may be more elaborate than so far recognized.
CONCLUSIONS AND FUTURE
PERSPECTIVES FOR BIOMARKER
RESEARCH
JDM is a multisystem disease. Not only the skin and
skeletal muscles are affected, but also other organ systems
and tissues such as the lungs, heart and intestines are
frequently (subclinically) involved and may be under-evaluated.
Vasculopathy due to loss and dysfunction of endothelial
cells as a result of the inflammatory process is thought to
underlie the symptoms in most of these organs and tissues.
Monitoring of disease activity and damage in all of these
affected tissues is important during clinical follow-up, as these
are key determinants for the long-term outcomes of patients.
Tools for monitoring of tissue activity and damage include
histopathological investigation of biopsies, and laboratory testing
of blood for specific biomarkers as well as several imaging
methods. Each of these methods has their strengths and
weaknesses and can be of value for specific diagnostic questions at
disease onset or during follow-up, as outlined in the consensus-
based recommendations for the management of JDM (135, 192).
There is still a need for minimally invasive, but at the same
time sensitive and specific diagnostic methods that correlate well
with clinical symptoms or reflect low-grade, local inflammation.
Tissue-specific biomarkers can therefore be of great value as a
monitoring tool.
To be able to identify sensitive, robust and reliable biomarkers
or developmonitoring tools, it is of key importance to set up well-
defined and large prospective patient cohorts, with a thorough
longitudinal collection of a standardized clinical dataset assessing
disease activity and organ involvement, paired with collection
of patient material (193). Such a dataset is required to ensure a
strict definition of active and inactive disease [e.g., as proposed by
Almeida et al. (72)]. An important consideration for a successful
biomarker study is the timing of data and sample collection:
depending on the purpose of the biomarker, time points before
start of immunosuppressive treatment, before each adjustment of
medication, during flares, at paired time points during active and
inactive disease or even at regular intervals of max 3–4 months
may be crucial to reliably investigate the potency of a biomarker.
Next to the “classical” statistical approach, comparing patients
with active disease and patients in remission (cross-sectionally
or in paired samples), new computational approaches providing
analysis methods that can integrate longitudinal data from
multiple patients and multiple (bio)markers or scoring tools
should be considered. These methods take into account the
fluctuating nature of a relapsing-remitting disease such as JDM
and are therefore better suited to test the reliability of a tool
that will be used for longitudinal follow-up in clinical practice
(194, 195).
To achieve implementation of a marker or tool into clinical
practice, both clinical and technical validation in independent
cohorts is of utmost importance. Only few markers prove to be
stable, reliable and easy to measure, which are key features for
a marker or tool to be suited for implementation into clinical
practice. Also the invasiveness of the method should be taken
into account. Ideally, a period of experimental implementation
can demonstrate the added value and feasibility of a marker or
tool in clinical practice. To achieve all this in a large group of
JDM patients to ensure sufficient statistical power, international
networks with well-established collaborations are fundamental.
Eventually, monitoring of disease activity with a reliable
tool can be used to guide treatment and thereby facilitate
precision medicine, with high dose therapy when indicated
but also preventing overtreatment. This may reduce both the
duration of active disease and thereby the disease-inflicted
damage, and medication side effects, which will benefit the
long-term outcomes on various domains, such as muscle
Frontiers in Immunology | www.frontiersin.org 14 December 2018 | Volume 9 | Article 2951
Wienke et al. Biomarkers and Immunopathogenesis in JDM
weakness, organ damage, cardiopulmonary fitness, and quality
of life. Next to facilitating personalized treatment strategies,
newly identified biomarkers may also provide insights into
the immunopathogenesis of JDM and provide new treatment
targets. For instance, new treatment strategies targeting the
IFN signature, such as anti-IFN antibodies (sifalimumab) or
JAK-inhibition (ruxolitinib) have been shown to reduce the
IFN signature in blood and muscle of adult dermatomyositis
patients, and may therefore be promising new strategies
for patients with JDM (186, 196, 197). Several studies
discussed in this review suggest a strong link between the
IFN signature and vasculopathy; and vasculopathy has been
related to disease severity. Targeting the IFN signature may
thus benefit vascularization in JDM and thereby improve
outcomes.
AUTHOR CONTRIBUTIONS
JW collected literature and wrote the manuscript draft. FvW
and AvR-K supervised JW, outlined the manuscript focus and
revised the manuscript. CD and LW critically revised the
manuscript.
FUNDING
JW is funded by the Bas Stichting, the Princess Beatrix
Muscle Foundation and Innovatiefonds Zorgverzekeraars. LW
and CD are supported by the NIHR Biomedical Research
Centre at Great Ormond Street Hospital and by grants from
Arthritis Research UK (21953), Cure-JM, and The Myositis
Association.
REFERENCES
1. Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J.
Incidence and prevalence of inflammatory myopathies: a systematic review.
Rheumatology (2015) 54:50–63. doi: 10.1093/rheumatology/keu289
2. Miller FW, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR,
et al. Genome-wide association study of dermatomyositis reveals genetic
overlap with other autoimmune disorders. Arthritis Rheum. (2013) 65:3239–
47. doi: 10.1093/med/9780199732920.003.0012
3. Miller FW, Chen W, O’Hanlon TP, Cooper RG, Vencovsky J, Rider LG,
et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype
alleles as major genetic risk factors for myositis phenotypes. Genes Immun.
(2015) 16:470–80. doi: 10.1038/gene.2015.28
4. Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J,
et al. Dense genotyping of immune-related loci in idiopathic inflammatory
myopathies confirms HLA alleles as the strongest genetic risk factor
and suggests different genetic background for major clinical subgroups.
Ann Rheum Dis. (2016) 75:1558–66. doi: 10.1136/annrheumdis-2015-
208119
5. Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments
in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol.
(2009) 23:665–78. doi: 10.1016/j.berh.2009.07.007
6. Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser
M, et al. 2017 European League Against Rheumatism/American College
of Rheumatology classification criteria for adult and juvenile idiopathic
inflammatory myopathies and their major subgroups. Ann Rheum Dis.
(2017) 76:1955–64. doi: 10.1136/annrheumdis-2017-211468
7. Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser
M, et al. 2017 European League Against Rheumatism/American College
of Rheumatology classification criteria for adult and juvenile idiopathic
inflammatory myopathies and their major subgroups. Arthritis Rheumatol.
(2017) 69:2271–82. doi: 10.1002/art.40320
8. Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, et al.
Clinical and laboratory features of fatal rapidly progressive interstitial
lung disease associated with juvenile dermatomyositis. Rheumatology (2015)
54:784–91. doi: 10.1093/rheumatology/keu385
9. Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff
IN, et al. Early illness features associated with mortality in the juvenile
idiopathic inflammatory myopathies. Arthritis Care Res. (2014) 66:732–40.
doi: 10.1002/acr.22212
10. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis
and other idiopathic inflammatory myopathies of childhood. Lancet (2008)
371:2201–12. doi: 10.1016/S0140-6736(08)60955-1
11. Huber A, Feldman BM. Long-term outcomes in juvenile dermatomyositis:
how did we get here and where are we going? Curr Rheumatol Rep. (2005)
7:441–6. doi: 10.1007/s11926-005-0048-1
12. Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic
review of juvenile-onset clinically amyopathic dermatomyositis. Br J
Dermatol. (2007) 157:637–44. doi: 10.1111/j.1365-2133.2007.08055.x
13. Plamondon S, Dent PB. Juvenile amyopathic dermatomyositis: results of a
case finding descriptive survey. J Rheumatol. (2000) 27:2031–4.
14. Oberle EJ, Bayer ML, Chiu YE, Co DO. How often are pediatric patients with
clinically amyopathic dermatomyositis truly amyopathic? Pediatr Dermatol.
(2017) 34:50–7. doi: 10.1111/pde.13013
15. Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG. Features
distinguishing clinically amyopathic juvenile dermatomyositis from
juvenile dermatomyositis. Rheumatology (2018) 57:1956–1963.
doi: 10.1093/rheumatology/key190
16. Rider LG, Nistala K. The juvenile idiopathic inflammatory
myopathies: pathogenesis, clinical and autoantibody phenotypes,
and outcomes. J Intern Med. (2016) 280:24–38. doi: 10.1111/joim.
12444
17. Rider LG. The heterogeneity of juvenile myositis. Autoimmun Rev. (2007)
6:241–7. doi: 10.1016/j.autrev.2006.08.009
18. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al.
Medium- and long-term functional outcomes in a multicenter cohort of
children with juvenile dermatomyositis. Arthritis Rheum. (2000) 43:541–9.
doi: 10.1002/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T
19. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive
management of juvenile dermatomyositis results in improved outcome and
decreased incidence of calcinosis. J Am Acad Dermatol. (2002) 47:505–11.
doi: 10.1067/mjd.2002.122196
20. Holzer U, van Royen-Kerkhof A, van der Torre P, Kuemmerle-Deschner
J, Well C, Handgretinger R, et al. Successful autologous stem cell
transplantation in two patients with juvenile dermatomyositis. Scand J
Rheumatol. (2010) 39:88–92. doi: 10.3109/03009740903096622
21. Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic
implications of histopathology in childhood polydermatomyositis. Arthritis
Rheum. (1982) 25:126–39. doi: 10.1002/art.1780250203
22. Huemer C, Kitson H, Malleson PN, Sanderson S, Huemer M, Cabral DA,
et al. Lipodystrophy in patients with juvenile dermatomyositis–evaluation of
clinical and metabolic abnormalities. J Rheumatol. (2001) 28:610–5.
23. Verma S, Singh S, Bhalla AK, Khullar M. Study of subcutaneous fat in
children with juvenile dermatomyositis. Arthritis Rheum. (2006) 55:564–8.
doi: 10.1002/art.22108
24. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar
A, et al. Predictors of acquired lipodystrophy in juvenile-onset
dermatomyositis and a gradient of severity. Medicine (2008) 87:70–86.
doi: 10.1097/MD.0b013e31816bc604
25. Pouessel G, Deschildre A, Le Bourgeois M, Cuisset J-M, Catteau B, Karila
C, et al. The lung is involved in juvenile dermatomyositis. Pediatr Pulmonol.
(2013) 48:1016–25. doi: 10.1002/ppul.22742
Frontiers in Immunology | www.frontiersin.org 15 December 2018 | Volume 9 | Article 2951
Wienke et al. Biomarkers and Immunopathogenesis in JDM
26. Richardson AE, Warrier K, Vyas H. Respiratory complications of the
rheumatological diseases in childhood. Arch Dis Child (2016) 101:752–8.
doi: 10.1136/archdischild-2014-306049
27. Kobayashi S, Higuchi K, Tamaki H, Wada Y, Wada N, Kubo M, et al.
Characteristics of juvenile dermatomyositis in Japan. Acta Paediatr Jpn
Overseas Ed. (1997) 39:257–62.
28. Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al.
The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.
Medicine (2013) 92:25–41. doi: 10.1097/MD.0b013e31827f264d
29. Sanner H, Aalokken TM, Gran JT, Sjaastad I, Johansen B, Flato B. Pulmonary
outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis.
(2011) 70:86–91. doi: 10.1136/ard.2010.131433
30. Morinishi Y, Oh-Ishi T, Kabuki T, Joh K. Juvenile dermatomyositis: clinical
characteristics and the relatively high risk of interstitial lung disease. Mod
Rheumatol. (2007) 17:413–7. doi: 10.3109/s10165-007-0610-y
31. Cantez S, Gross GJ, MacLusky I, Feldman BM. Cardiac findings in children
with juvenile Dermatomyositis at disease presentation. Pediatr Rheumatol
Online J. (2017) 15:54. doi: 10.1186/s12969-017-0182-0
32. Pachman LM, Cooke N. Juvenile dermatomyositis: a
clinical and immunologic study. J Pediatr (1980) 96:226–34.
doi: 10.1016/S0022-3476(80)80807-9
33. Na S-J, Kim SM, Sunwoo IN, Choi Y-C. Clinical characteristics and outcomes
of juvenile and adult dermatomyositis. J Korean Med Sci. (2009) 24:715–21.
doi: 10.3346/jkms.2009.24.4.715
34. Constantin T, Ponyi A, Orban I, Molnar K, Derfalvi B, Dicso F,
et al. National registry of patients with juvenile idiopathic inflammatory
myopathies in Hungary–clinical characteristics and disease course of 44
patients with juvenile dermatomyositis. Autoimmunity (2006) 39:223–32.
doi: 10.1080/08916930600622819
35. Shehata R, al-Mayouf S, al-Dalaan A, al-Mazaid A, al-Balaa S, Bahabri S.
Juvenile dermatomyositis: clinical profile and disease course in 25 patients.
Clin Exp Rheumatol. (1999) 17:115–118.
36. Schwartz T, Sanner H, Gjesdal O, Flato B, Sjaastad I. In juvenile
dermatomyositis, cardiac systolic dysfunction is present after long-term
follow-up and is predicted by sustained early skin activity. Ann Rheum Dis.
(2014) 73:1805–10. doi: 10.1136/annrheumdis-2013-203279
37. Schwartz T, Sanner H, Husebye T, Flato B, Sjaastad I. Cardiac dysfunction
in juvenile dermatomyositis: a case-control study. Ann Rheum Dis. (2011)
70:766–71. doi: 10.1136/ard.2010.137968
38. Schwartz T, Diederichsen LP, Lundberg IE, Sjaastad I, Sanner H.
Cardiac involvement in adult and juvenile idiopathic inflammatory
myopathies. RMD open (2006) 2:e000291. doi: 10.1136/rmdopen-2016-
000291
39. Jimenez C, Rowe PC, Keene D. Cardiac and central nervous system
vasculitis in a child with dermatomyositis. J Child Neurol (1994) 9:297–300.
doi: 10.1177/088307389400900315
40. Ramanan AV, Sawhney S, Murray KJ. Central nervous system complications
in two cases of juvenile onset dermatomyositis. Rheumatology (2001)
40:1293–8. doi: 10.1093/rheumatology/40.11.1293
41. Silverberg JI, Kwa L, KwaMC, Laumann AE, Ardalan K. Cardiovascular and
cerebrovascular comorbidities of juvenile dermatomyositis in US children:
an analysis of the National Inpatient Sample. Rheumatology (2018) 57:694–
702. doi: 10.1093/rheumatology/kex465
42. Robinson AB, Hoeltzel MF, Wahezi DM, Becker ML, Kessler EA, Schmeling
H, et al. Clinical characteristics of children with juvenile dermatomyositis:
the Childhood Arthritis and Rheumatology Research Alliance Registry.
Arthritis Care Res. (2014) 66:404–10. doi: 10.1002/acr.22142
43. Laskin BL, Choyke P, Keenan GF, Miller FW, Rider LG. Novel
gastrointestinal tract manifestations in juvenile dermatomyositis. J Pediatr.
(1999) 135:371–4. doi: 10.1016/S0022-3476(99)70137-X
44. Mamyrova G, Kleiner DE, James-Newton L, Shaham B, Miller FW, Rider
LG. Late-onset gastrointestinal pain in juvenile dermatomyositis as a
manifestation of ischemic ulceration from chronic endarteropathy. Arthritis
Rheum. (2007) 57:881–4. doi: 10.1002/art.22782
45. Varsani H, Charman SC, Li CK, Marie SKN, Amato AA, Banwell B, et al.
Validation of a score tool for measurement of histological severity in juvenile
dermatomyositis and association with clinical severity of disease.Ann Rheum
Dis. (2015) 74:204–10. doi: 10.1136/annrheumdis-2013-203396
46. Besancon A, Brochard K, Dupic L, Gitiaux C, Delville M, Krid S,
et al. Presentations and outcomes of juvenile dermatomyositis patients
admitted to intensive care units. Rheumatology (2017) 56:1814–6.
doi: 10.1093/rheumatology/kex267
47. Meneghel A, Martini G, Birolo C, Tosoni A, Pettenazzo A, Zulian F. Life-
threatening systemic capillary leak syndrome in juvenile dermatomyositis.
Rheumatology (2017) 56:1822–3. doi: 10.1093/rheumatology/kex262
48. Goncalves FGP, Chimelli L, Sallum AME, Marie SKN, Kiss MHB, Ferriani
VPL. Immunohistological analysis of CD59 and membrane attack complex
of complement in muscle in juvenile dermatomyositis. J Rheumatol. (2002)
29:1301–7.
49. Yu HH, Chang HM, Chiu CJ, Yang YH, Lee JH, Wang LC, et al. Detection of
anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients
with juvenile dermatomyositis. J Microbiol Immunol Infect. (2016) 49:264–
70. doi: 10.1016/j.jmii.2014.05.012
50. Karasawa R, Tamaki M, Sato T, Tanaka M, Nawa M, Yudoh K,
et al. Multiple target autoantigens on endothelial cells identified in
juvenile dermatomyositis using proteomics. Rheumatology (2018) 57:671–6.
doi: 10.1093/rheumatology/kex468
51. Whitaker JN, Engel WK. Vascular deposits of immunoglobulin and
complement in idiopathic inflammatory myopathy. N Engl J Med. (1972)
286:333–8. doi: 10.1056/NEJM197202172860701
52. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of
complement membrane attack complex in dermatomyositis. N Engl J Med.
(1986) 314:329–34. doi: 10.1056/NEJM198602063140601
53. Kissel JT, Halterman RK, Rammohan KW, Mendell JR. The relationship
of complement-mediated microvasculopathy to the histologic features and
clinical duration of disease in dermatomyositis. Arch Neurol. (1991) 48:26–
30. doi: 10.1001/archneur.1991.00530130034016
54. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced
dermatomyositis: a quantitative study. Ann Neurol. (1990) 27:343–56.
doi: 10.1002/ana.410270402
55. Gitiaux C, De Antonio M, Aouizerate J, Gherardi RK, Guilbert T, Barnerias
C, et al. Vasculopathy-related clinical and pathological features are associated
with severe juvenile dermatomyositis. Rheumatology (2016) 55:470–9.
doi: 10.1093/rheumatology/kev359
56. Schmeling H, Stephens S, Goia C, Manlhiot C, Schneider R, Luthra S, et al.
Nailfold capillary density is importantly associated over time with muscle
and skin disease activity in juvenile dermatomyositis. Rheumatology (2011)
50:885–93. doi: 10.1093/rheumatology/keq407
57. Feldman BM, Rider LG, Dugan L, Miller FW, Schneider R. Nailfold
capillaries as indicators of disease activity in juvenile idiopathic
inflammatory myopathies (JIIM). Arthritis Rheum. (1999) 42:S181.
58. Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement
in juvenile dermatomyositis is associated with loss of end row nailfold
capillary loops. J Rheumatol. (2004) 31:1644–9.
59. Bertolazzi C, Cutolo M, Smith V, Gutierrez M. State of the art on nailfold
capillaroscopy in dermatomyositis and polymyositis. Semin Arthritis Rheum.
(2017) 47:432–44. doi: 10.1016/j.semarthrit.2017.06.001
60. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al.
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion
body myositis: physician and Patient/Parent Global Activity, Manual Muscle
Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood
Health Assessment Questionnaire (C-HAQ). Arthritis Care Res. (2011)
63(Suppl. 1):S118–57.
61. Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini
EH, et al. Development of validated disease activity and damage indices
for the juvenile idiopathic inflammatory myopathies. II The Childhood
Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of
muscle function The Juvenile Dermatomyositis, D. Arthritis Rheum. (1999)
42:2213–9.
62. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR,Whitney-Mahoney K,
et al. Validation of manual muscle testing and a subset of eight muscles for
adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res.
(2010) 62:465–72. doi: 10.1002/acr.20035
63. Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB,
Zemel LS, et al. Development of validated disease activity and damage
indices for the juvenile idiopathic inflammatory myopathies: I. Physician,
Frontiers in Immunology | www.frontiersin.org 16 December 2018 | Volume 9 | Article 2951
Wienke et al. Biomarkers and Immunopathogenesis in JDM
parent, and patient global assessments Juvenile Dermatomyositis Disease
Activity Collaborative Study Group. Arthritis Rheum. (1997) 40:1976–83.
doi: 10.1002/art.1780401109
64. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel
LS, et al. Preliminary validation and clinical meaning of the Cutaneous
Assessment Tool in juvenile dermatomyositis. Arthritis Rheum. (2008)
59:214–21. doi: 10.1002/art.23340
65. Huber AM, Lachenbruch PA, Dugan EM, Miller FW, Rider LG. Alternative
scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis:
results using abbreviated formats. Arthritis Rheum. (2008) 59:352–6.
doi: 10.1002/art.23313
66. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM.
Disease activity score for children with juvenile dermatomyositis:
reliability and validity evidence. Arthritis Rheum. (2003) 49:7–15.
doi: 10.1002/art.10924
67. Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm
RM, et al. Validation of the Childhood Health Assessment Questionnaire
in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease
Activity Collaborative Study Group. J Rheumatol. (2001) 28:1106–11.
68. Tiao J, Feng R, Berger EM, Brandsema JF, Coughlin CC, Khan N, et al.
Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area
and Severity Index and the Cutaneous Assessment Tool-Binary Method in
juvenile dermatomyositis among paediatric dermatologists, rheumatologists
and neurologists. Br J Dermatol. (2017) 177:1086–92. doi: 10.1111/bjd.15596
69. Sultan SM, Allen E, Cooper RG, Agarwal S, Kiely P, Oddis CV, et al. Interrater
reliability and aspects of validity of the myositis damage index. Ann Rheum
Dis. (2011) 70:1272–6. doi: 10.1136/ard.2010.142117
70. McCann LJ, Kirkham JJ, Wedderburn LR, Pilkington C, Huber AM, Ravelli
A, et al. Development of an internationally agreed minimal dataset for
juvenile dermatomyositis (JDM) for clinical and research use. Trials 16:268.
doi: 10.1186/s13063-015-0784-0
71. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A,
Pilkington C, et al. The PRINTO criteria for clinically inactive disease
in juvenile dermatomyositis. Ann Rheum Dis. (2013) 72:686–93.
doi: 10.1136/annrheumdis-2012-201483
72. Almeida B, Campanilho-Marques R, Arnold K, Pilkington CA, Wedderburn
LR, Nistala K. Analysis of published criteria for clinically inactive
disease in a large juvenile dermatomyositis cohort shows that skin
disease is underestimated. Arthritis Rheumatol. (2015) 67:2495–502.
doi: 10.1002/art.39200
73. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and
clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. (2011)
13:209. doi: 10.1186/ar3275
74. Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis,
and treatment of the idiopathic inflammatory myopathies. JAMA (2011)
305:183–90. doi: 10.1001/jama.2010.1977
75. Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff
IN, et al. The myositis autoantibody phenotypes of the juvenile
idiopathic inflammatory myopathies. Medicine (2013) 92:223–43.
doi: 10.1097/MD.0b013e31829d08f9
76. Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena
H, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and
associated clinical phenotype in a large UK cohort. J Autoimmun. (2017)
84:55–64. doi: 10.1016/j.jaut.2017.06.007
77. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J,
Chinoy H, et al. Clinical associations of autoantibodies to a p155/140 kDa
doublet protein in juvenile dermatomyositis. Rheumatology (2008) 47:324–8.
doi: 10.1093/rheumatology/kem359
78. Habers GEA, Huber AM, Mamyrova G, Targoff IN, O’Hanlon TP, Adams S,
et al. Brief Report: association of myositis autoantibodies, clinical features,
and environmental exposures at illness onset with disease course in juvenile
myositis. Arthritis Rheumatol. (2016) 68:761–8. doi: 10.1002/art.39466
79. Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K,
Wedderburn LR, et al. Calcinosis in juvenile dermatomyositis is influenced
by both anti-NXP2 autoantibody status and age at disease onset.
Rheumatology (2014) 53:2204–8. doi: 10.1093/rheumatology/keu259
80. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North
J, Ollier WER, et al. Autoantibodies to a 140-kd protein in juvenile
dermatomyositis are associated with calcinosis. Arthritis Rheum. (2009)
60:1807–14. doi: 10.1002/art.24547
81. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al.
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients
with clinically amyopathic dermatomyositis. Arthritis Rheum. (2005)
52:1571–6. doi: 10.1002/art.21023
82. Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM,
Pilkington C, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis
identify a distinct clinical phenotype: a prospective cohort study. Arthritis
Res Ther. (2016) 16:R138. doi: 10.1186/ar4600
83. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori
T. Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance
for patients with dermatomyositis. Rheumatology (2010) 49:1726–33.
doi: 10.1093/rheumatology/keq153
84. Hall JC, Casciola-Rosen L, Samedy L-A, Werner J, Owoyemi K, Danoff
SK, et al. Anti-melanoma differentiation-associated protein 5-associated
dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. (2013)
65:1307–15. doi: 10.1002/acr.21992
85. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The
mucocutaneous and systemic phenotype of dermatomyositis patients with
antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad
Dermatol. (2011) 65:25–34. doi: 10.1016/j.jaad.2010.09.016
86. Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M,
et al. Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory
myopathies identify a rare but clinically important subset of patients. J
Rheumatol. (2017) 44:488–492. doi: 10.3899/jrheum.160871
87. Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy
PL, et al. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A
reductase autoantibodies with DRB1∗07:01 and severe myositis in juvenile
myositis patients. Arthritis Care Res. (2017) 69:1088–94. doi: 10.1002/acr.
23113
88. Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, et al.
Autoantibody levels in myositis patients correlate with clinical response
during B cell depletion with rituximab. Rheumatology (2016) 55:991–9.
doi: 10.1093/rheumatology/kev444
89. O’Connor KA, Abbott KA, Sabin B, Kuroda M, Pachman LM. MxA gene
expression in juvenile dermatomyositis peripheral blood mononuclear cells:
association with muscle involvement. Clin Immunol. (2006) 120:319–25.
90. Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated
serum interferon-alpha activity in juvenile dermatomyositis: associations
with disease activity at diagnosis and after thirty-six months of therapy.
Arthritis Rheum. (2009) 60:1815–24. doi: 10.1002/art.24555
91. Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in
adult and juvenile dermatomyositis. Arthritis Res Ther. (2011) 13:249.
doi: 10.1186/ar3531
92. Sanner H, Schwartz T, Flato B, Vistnes M, Christensen G, Sjaastad I.
Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis
median 16.8 years after disease onset; associations with disease
activity, duration and organ damage. PLoS ONE (2014) 9:e92171.
doi: 10.1371/journal.pone.0092171
93. Bellutti Enders F, van Wijk F, Scholman R, Hofer M, Prakken BJ, van Royen-
Kerkhof A, et al. Correlation of CXCL10, tumor necrosis factor receptor type
II, and galectin 9 with disease activity in juvenile dermatomyositis. Arthritis
Rheumatol. (2014) 66:2281–9. doi: 10.1002/art.38676
94. Enders FB, Delemarre EM, Kuemmerle-Deschner J, van der Torre P,
Wulffraat NM, Prakken BP, et al. Autologous stem cell transplantation leads
to a change in proinflammatory plasma cytokine profile of patients with
juvenile dermatomyositis correlating with disease activity. Ann Rheum Dis.
(2015) 74:315–7. doi: 10.1136/annrheumdis-2014-206287
95. Kobayashi I, Ono S, Kawamura N, Okano M, Kobayashi K. Elevated serum
levels of soluble interleukin-2 receptor in juvenile dermatomyositis.
Pediatr Int. (2001) 43:109–11. doi: 10.1046/j.1442-200x.2001.
01367.x
96. De Benedetti F, De Amici M, Aramini L, Ruperto N, Martini A. Correlation
of serum neopterin concentrations with disease activity in juvenile
dermatomyositis. Arch Dis Child. (1993) 69:232–5. doi: 10.1136/adc.69.2.232
97. Rider LG, Schiffenbauer AS, Zito M, Lim KL, Ahmed A, Zemel LS, et al.
Neopterin and quinolinic acid are surrogate measures of disease activity
Frontiers in Immunology | www.frontiersin.org 17 December 2018 | Volume 9 | Article 2951
Wienke et al. Biomarkers and Immunopathogenesis in JDM
in the juvenile idiopathic inflammatory myopathies. Clin Chem. (2002)
48:1681–8.
98. Nistala K, Varsani H, Wittkowski H, Vogl T, Krol P, Shah V, et al. Myeloid
related protein induces muscle derived inflammatory mediators in juvenile
dermatomyositis. Arthritis Res Ther. (2013) 15:R131. doi: 10.1186/ar4311
99. Haas RH, Dyck RF, Dubowitz V, Pepys MB. C-reactive protein
in childhood dermatomyositis. Ann Rheum Dis. (1982) 41:483–5.
doi: 10.1136/ard.41.5.483
100. Eisenstein DM, O’Gorman MR, Pachman LM. Correlations between change
in disease activity and changes in peripheral blood lymphocyte subsets in
patients with juvenile dermatomyositis. J Rheumatol. (1997) 24:1830–2.
101. Elst EF, Klein M, de Jager W, Kamphuis S, Wedderburn LR, van der Zee R,
et al. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive
T cells in patients with juvenile dermatomyositis. Arthritis Rheum. (2008)
58:547–55. doi: 10.1002/art.23202
102. Morita R, Schmitt N, Bentebibel S-E, Ranganathan R, Bourdery
L, Zurawski G, et al. Human blood CXCR5(+)CD4(+)
T cells are counterparts of T follicular cells and contain
specific subsets that differentially support antibody secretion.
Immunity (2011) 34:108–21. doi: 10.1016/j.immuni.2010.
12.012
103. Ernste FC, Crowson CS, de Padilla CL, Hein MS, Reed AM. Longitudinal
peripheral blood lymphocyte subsets correlate with decreased disease
activity in juvenile dermatomyositis. J Rheumatol. (2013) 40:1200–11.
doi: 10.3899/jrheum.121031
104. Vercoulen Y, Bellutti Enders F, Meerding J, Plantinga M, Elst EF, Varsani H,
et al. Increased presence of FOXP3+ regulatory T cells in inflamed muscle of
patients with active juvenile dermatomyositis compared to peripheral blood.
PLoS ONE (2014) 9:e105353. doi: 10.1371/journal.pone.0105353
105. Lopez De Padilla CM, Crowson CS, Hein MS, Pendegraft RS, Strausbauch
MA, Niewold TB, et al. Gene expression profiling in blood and affected
muscle tissues reveals differential activation pathways in patients with new-
onset juvenile and adult dermatomyositis. J Rheumatol. (2017) 44:117–24.
doi: 10.3899/jrheum.160293
106. Piper CJM, Wilkinson MGL, Deakin CT, Otto GW, Dowle S, Duurland
CL, et al. CD19(+)CD24(hi)CD38(hi) B cells are expanded in juvenile
dermatomyositis and exhibit a pro-inflammatory phenotype after activation
through toll-like receptor 7 and interferon-alpha. Front Immunol. (2018)
9:1372. doi: 10.3389/fimmu.2018.01372
107. Guzman J, Petty RE, Malleson PN. Monitoring disease activity in juvenile
dermatomyositis: the role of von Willebrand factor and muscle enzymes. J
Rheumatol. (1994) 21:739–43.
108. Bloom BJ, Tucker LB, Miller LC, Schaller JG. von Willebrand factor in
juvenile dermatomyositis. J Rheumatol. (1995) 22:320–5.
109. Scott JP, Arroyave C. Activation of complement and coagulation
in juvenile dermatomyositis. Arthritis Rheum. (1987) 30:572–6.
doi: 10.1002/art.1780300513
110. Xu D, Huang C-C, Kachaochana A, Morgan GA, Bonaldo MF, Soares MB,
et al. MicroRNA-10a regulation of proinflammatorymediators: an important
component of untreated juvenile dermatomyositis. J Rheumatol. (2016)
43:161–8. doi: 10.3899/jrheum.141474
111. Xu D, Kacha-Ochana A, Morgan GA, Huang C-C, Pachman LM. Endothelial
progenitor cell number is not decreased in 34 children with Juvenile
Dermatomyositis: a pilot study. Pediatr Rheumatol Online J. (2017) 15:42.
doi: 10.1186/s12969-017-0171-3
112. Coyle K, Rother KI, Weise M, Ahmed A, Miller FW, Rider LG. Metabolic
abnormalities and cardiovascular risk factors in children with myositis. J
Pediatr. (2009) 155:882–7. doi: 10.1016/j.jpeds.2009.06.009
113. Kozu KT, Silva CA, Bonfa E, Sallum AM, Pereira RMR, Viana VS, et al.
Dyslipidaemia in juvenile dermatomyositis: the role of disease activity. Clin
Exp Rheumatol. (2013) 31:638–44.
114. Olazagasti JM, Hein M, Crowson CS, de Padilla CL, Peterson E,
Baechler EC, et al. Adipokine gene expression in peripheral blood
of adult and juvenile dermatomyositis patients and their relation to
clinical parameters and disease activity measures. J Inflamm. (2015) 12:29.
doi: 10.1186/s12950-015-0075-2
115. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J,
et al. An interferon signature in the peripheral blood of dermatomyositis
patients is associated with disease activity. Mol Med. (2007) 13:59–68.
doi: 10.2119/2006-00085.Baechler
116. Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al.
Interleukin-6 and type I interferon-regulated genes and chemokines mark
disease activity in dermatomyositis. Arthritis Rheum. (2009) 60:3436–46.
doi: 10.1002/art.24936
117. Reed AM, Peterson E, Bilgic H, Ytterberg SR, Amin S, Hein MS, et al.
Changes in novel biomarkers of disease activity in juvenile and adult
dermatomyositis are sensitive biomarkers of disease course.Arthritis Rheum.
(2012) 64:4078–86. doi: 10.1002/art.34659
118. Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne
PA, et al. Elevated serum levels of interleukin-1 receptor antagonist in
polymyositis/dermatomyositis. A biologic marker of disease activity with a
possible role in the lack of acute-phase protein response. Arthritis Rheum.
(1994) 37:1744–51. doi: 10.1002/art.1780371206
119. Krystufkova O, Vallerskog T, Helmers SB, Mann H, Putova I, Belacek J,
et al. Increased serum levels of B cell activating factor (BAFF) in subsets of
patients with idiopathic inflammatory myopathies. Ann Rheum Dis. (2009)
68:836–43. doi: 10.1136/ard.2008.091405
120. Lopez De Padilla CM, McNallan KT, Crowson CS, Bilgic H, Bram RJ,
Hein MS, et al. BAFF expression correlates with idiopathic inflammatory
myopathy disease activity measures and autoantibodies. J Rheumatol. (2013)
40:294–302. doi: 10.3899/jrheum.120555
121. Ishida T, Matsumoto Y, Ohashi M, Sasaki R. Analysis of
lymphocyte subpopulations in peripheral blood in adult and
juvenile cases of dermatomyositis. J Dermatol. (1993) 20:30–4.
doi: 10.1111/j.1346-8138.1993.tb03825.x
122. Aleksza M, Szegedi A, Antal-Szalmas P, Irinyi B, Gergely L, Ponyi A,
et al. Altered cytokine expression of peripheral blood lymphocytes in
polymyositis and dermatomyositis. Ann Rheum Dis. (2005) 64:1485–9.
doi: 10.1136/ard.2003.017715
123. Kubo M, Ihn H, Yamane K, Yazawa N, Kikuchi K, Soma Y, et al. Increased
serum levels of soluble vascular cell adhesion molecule-1 and soluble E-
selectin in patients with polymyositis/dermatomyositis. Br J Dermatol. (2000)
143:392–8. doi: 10.1046/j.1365-2133.2000.03668.x
124. Bloom BJ, Miller LC, Blier PR. Soluble adhesion molecules in pediatric
rheumatic diseases. J Rheumatol. (2002) 29:832–6.
125. McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson
JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry
and Repository (UK and Ireland)–clinical characteristics of children
recruited within the first 5 yr. Rheumatology (2006) 45:1255–60.
doi: 10.1093/rheumatology/kel099
126. Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink
CW, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of
79 children. J Rheumatol. (1998) 25:1198–204.
127. Targoff IN. Laboratory manifestations of polymyositis/dermatomyositis.
Clin Dermatol. (1988) 6:76–92. doi: 10.1016/0738-081X(88)90051-X
128. Mathiesen PR, Zak M, Herlin T, Nielsen SM. Clinical features and outcome
in aDanish cohort of juvenile dermatomyositis patients.Clin Exp Rheumatol.
(2010) 28:782–9.
129. Ntusi NBA, Heckmann JM. Myopathy with a normal creatine kinase level in
juvenile myopathic dermatomyositis. S Afr Med J. (2010) 100:24–5.
130. Hinderks GJ, Frolich J. Low serum creatine kinase values associated with
administration of steroids. Clin Chem. (1979) 25:2050–1.
131. Kagen LJ, Aram S. Creatine kinase activity inhibitor in sera from
patients with muscle disease. Arthritis Rheum. (1987) 30:213–7.
doi: 10.1002/art.1780300212
132. Rider LG, Miller FW. Laboratory evaluation of the inflammatory
myopathies. Clin Diagn Lab Immunol. (1995) 2:1–9.
133. Naim MY, Reed AM. Enzyme elevation in patients with juvenile
dermatomyositis and steroid myopathy. J Rheumatol. (2006) 33:1392–4.
134. Hinze CH, Oommen PT, Dressler F, Urban A, Weller-Heinemann F, Speth
F, et al. Development of practice and consensus-based strategies including a
treat-to-target approach for themanagement ofmoderate and severe juvenile
dermatomyositis in Germany andAustria. Pediatr Rheumatol Online J (2018)
16:40. doi: 10.1186/s12969-018-0257-6
135. Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova
P, Feldman BM, et al. Consensus-based recommendations for the
Frontiers in Immunology | www.frontiersin.org 18 December 2018 | Volume 9 | Article 2951
Wienke et al. Biomarkers and Immunopathogenesis in JDM
management of juvenile dermatomyositis. Ann Rheum Dis. (2017) 76:329–
40. doi: 10.1136/annrheumdis-2016-209247
136. Rice GI, Melki I, Fremond M-L, Briggs TA, Rodero MP, Kitabayashi N, et al.
Assessment of type I interferon signaling in pediatric inflammatory disease.
J Clin Immunol. (2017) 37:123–32. doi: 10.1007/s10875-016-0359-1
137. Fall N, Bove KE, Stringer K, Lovell DJ, Brunner HI, Weiss J, et al. Association
between lack of angiogenic response in muscle tissue and high expression
of angiostatic ELR-negative CXC chemokines in patients with juvenile
dermatomyositis: possible link to vasculopathy. Arthritis Rheum. (2005)
52:3175–80. doi: 10.1002/art.21303
138. Rodero MP, Decalf J, Bondet V, Hunt D, Rice GI, Werneke S, et al. Detection
of interferon alpha protein reveals differential levels and cellular sources in
disease. J Exp Med. (2017) 214:1547–55. doi: 10.1084/jem.20161451
139. van den Hoogen LL, van Roon JAG, Mertens JS, Wienke J, Lopes AP, de
Jager W, et al. Galectin-9 is an easy to measure biomarker for the interferon
signature in systemic lupus erythematosus and antiphospholipid syndrome.
Ann RheumDis. (2018) 77:1810–14. doi: 10.1136/annrheumdis-2018-213497
140. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER.
Neopterin as marker for activation of cellular immunity: immunologic
basis and clinical application. Adv Clin Chem. (1989) 27:81–141.
doi: 10.1016/S0065-2423(08)60182-1
141. Holzinger D, Frosch M, Kastrup A, Prince FHM, Otten MH, Van Suijlekom-
Smit LWA, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex
is a sensitive indicator for disease activity and predicts relapses in systemic-
onset juvenile idiopathic arthritis. Ann Rheum Dis. (2012) 71:974–80.
doi: 10.1136/annrheumdis-2011-200598
142. Silverman ED, Laxer RM, Nelson DL, Rubin LA. Soluble interleukin-2
receptor in juvenile rheumatoid arthritis. J Rheumatol. (1991) 18:1398–402.
143. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga
T. Anti-melanoma differentiation-associated gene 5 antibody is
a diagnostic and predictive marker for interstitial lung diseases
associated with juvenile dermatomyositis. J Pediatr. (2011) 158:675–7.
doi: 10.1016/j.jpeds.2010.11.033
144. Kobayashi I, Ono S, Kawamura N, Okano M, Miyazawa K, Shibuya H, et al.
KL-6 is a potential marker for interstitial lung disease associated with juvenile
dermatomyositis. J Pediatr. (2001) 138:274–6. doi: 10.1067/mpd.2001.110324
145. Kobayashi N, Kobayashi I, Mori M, Sato S, Iwata N, Shigemura T,
et al. Increased serum B cell activating factor and a proliferation-
inducing ligand are associated with interstitial lung disease in patients
with juvenile dermatomyositis. J Rheumatol. (2015) 42:2412–8.
doi: 10.3899/jrheum.140977
146. Schwartz T, Sjaastad I, Flato B, Vistnes M, Christensen G, Sanner H. In
active juvenile dermatomyositis, elevated eotaxin andMCP-1 and cholesterol
levels in the upper normal range are associated with cardiac dysfunction.
Rheumatology (2014) 53:2214–22. doi: 10.1093/rheumatology/keu256
147. Barth Z, Nomeland Witczak B, Schwartz T, Gjesdal K, Flato B, Koller A,
et al. In juvenile dermatomyositis, heart rate variability is reduced, and
associated with both cardiac dysfunction and markers of inflammation: a
cross-sectional study median 13.5 years after symptom onset. Rheumatology
(2016) 55:535–43. doi: 10.1093/rheumatology/kev376
148. van SummerenMJH, Spliet WGM, van Royen-Kerkhof A, Vermeer C, Lilien
M, Kuis W, et al. Calcinosis in juvenile dermatomyositis: a possible role for
the vitamin K-dependent protein matrix Gla protein. Rheumatology (2008)
47:267–71. doi: 10.1093/rheumatology/kem360
149. Reed A, Haugen M, Pachman LM, Langman CB. Abnormalities in serum
osteocalcin values in children with chronic rheumatic diseases. J Pediatr.
(1990) 116:574–80. doi: 10.1016/S0022-3476(05)81605-1
150. Chinoy H, Salway F, John S, Fertig N, Tait BD, Oddis C V, et al.
Tumour necrosis factor-alpha single nucleotide polymorphisms are not
independent of HLA class I in UK Caucasians with adult onset
idiopathic inflammatory myopathies. Rheumatology (2007) 46:1411–6.
doi: 10.1093/rheumatology/kem145y
151. Lutz J, Huwiler KG, Fedczyna T, Lechman TS, Crawford S, Kinsella TR,
et al. Increased plasma thrombospondin-1 (TSP-1) levels are associated with
the TNF alpha-308A allele in children with juvenile dermatomyositis. Clin
Immunol. (2002) 103:260–3. doi: 10.1006/clim.2001.5212
152. Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Gene-
gene-sex interaction in cytokine gene polymorphisms revealed by serum
interferon alpha phenotype in juvenile dermatomyositis. J Pediatr. (2010)
157:653–7. doi: 10.1016/j.jpeds.2010.04.034
153. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP,
Kinder JM, et al. TNFalpha-308A allele in juvenile dermatomyositis:
association with increased production of tumor necrosis factor alpha, disease
duration, and pathologic calcifications. Arthritis Rheum. (2000) 43:2368–77.
doi: 10.1002/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8
154. Pachman LM, Fedczyna TO, Lechman TS, Lutz J. Juvenile dermatomyositis:
the association of the TNF alpha-308A allele and disease chronicity. Curr
Rheumatol Rep. (2001) 3:379–86. doi: 10.1007/s11926-996-0007-5
155. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N
Engl J Med. (1975) 292:344–7. doi: 10.1056/NEJM197502132920706
156. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts).
N Engl J Med. (1975) 292:403–7. doi: 10.1056/NEJM197502202920807
157. Wedderburn LR, Varsani H, Li CKC, Newton KR, Amato AA, Banwell B,
et al. International consensus on a proposed score system for muscle biopsy
evaluation in patients with juvenile dermatomyositis: a tool for potential use
in clinical trials.Arthritis Rheum. (2007) 57:1192–201. doi: 10.1002/art.23012
158. Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, et al.
Muscle biopsy findings in combination withmyositis-specific autoantibodies
aid prediction of outcomes in juvenile dermatomyositis.Arthritis Rheumatol.
(2016) 68:2806–16. doi: 10.1002/art.39753
159. Li CKC, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR. MHC Class
I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol.
(2004) 31:605–9.
160. SallumAME, KissMHB, Silva CAA,Wakamatsu A, Sachetti S, Lotufo S, et al.
MHC class I and II expression in juvenile dermatomyositis skeletal muscle.
Clin Exp Rheumatol. (2009) 27:519–26.
161. Sallum AME, Marie SKN, Wakamatsu A, Sachetti S, Vianna MAAG, Silva
CAA, et al. Immunohistochemical analysis of adhesion molecule expression
on muscle biopsy specimens from patients with juvenile dermatomyositis. J
Rheumatol. (2004) 31:801–7.
162. Sakuta R, Murakami N, Jin Y, Nagai T, Nonaka I, Nishino I.
Diagnostic significance of membrane attack complex and vitronectin
in childhood dermatomyositis. J Child Neurol. (2005) 20:597–602.
doi: 10.1177/08830738050200071201
163. Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG,
et al. Gene expression profiling in DQA1∗0501+ children with untreated
dermatomyositis: a novel model of pathogenesis. J Immunol. (2002)
168:4154–63. doi: 10.4049/jimmunol.168.8.4154
164. Shrestha S, Wershil B, Sarwark JF, Niewold TB, Philipp T, Pachman
LM. Lesional and nonlesional skin from patients with untreated juvenile
dermatomyositis displays increased numbers of mast cells and mature
plasmacytoid dendritic cells. Arthritis Rheum. (2010) 62:2813–22.
doi: 10.1002/art.27529
165. Wargula JC, Lovell DJ, Passo MH, Bove KE, Santangelo JD, Levinson JE.
What more can we learn from muscle histopathology in children with
dermatomyositis/polymyositis? Clin Exp Rheumatol. (2006) 24:333–43.
166. Soponkanaporn S, Deakin CT, Schutz PW, Marshall LR, Yasin SA, Johnson
CM, et al. Expression of myxovirus-resistance protein A: a possible
marker of muscle disease activity and autoantibody specificities in juvenile
dermatomyositis.Neuropathol Appl Neurobiol. (2018). [Epub ahead of print].
167. Gitiaux C, Latroche C, Weiss-Gayet M, Rodero MP, Duffy D,
Bader-Meunier B, et al. Myogenic progenitor cells exhibit type i
interferon-driven proangiogenic properties and molecular signature
during juvenile dermatomyositis. Arthritis Rheumatol. (2018) 70:134–45.
doi: 10.1002/art.40328
168. Minetti C, Gattorno M, Repetto S, Gregorio A, Pedemonte M, Assereto
S, et al. Chemokine receptor CCR7 is expressed in muscle fibers in
juvenile dermatomyositis. Biochem Biophys Res Commun. (2005) 333:540–
543. doi: 10.1016/j.bbrc.2005.05.146
169. Lopez de Padilla CM, Vallejo AN,McNallan KT, Vehe R, Smith SA, Dietz AB,
et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile
dermatomyositis. Arthritis Rheum. (2007) 56:1658–68.
170. Englund P, Nennesmo I, Klareskog L, Lundberg IE. Interleukin-
1alpha expression in capillaries and major histocompatibility complex
class I expression in type II muscle fibers from polymyositis and
dermatomyositis patients: important pathogenic features independent
Frontiers in Immunology | www.frontiersin.org 19 December 2018 | Volume 9 | Article 2951
Wienke et al. Biomarkers and Immunopathogenesis in JDM
of inflammatory cell clusters in muscle. Arthritis Rheum. (2002) 46:1044–55.
doi: 10.1002/art.10140
171. Kim E, Cook-Mills J, Morgan G, Sredni ST, Pachman LM. Increased
expression of vascular cell adhesion molecule 1 in muscle biopsy samples
from juvenile dermatomyositis patients with short duration of untreated
disease is regulated by miR-126. Arthritis Rheum. (2012) 64:3809–17.
doi: 10.1002/art.34606
172. Chen YW, Shi R, Geraci N, Shrestha S, Gordish-Dressman H, Pachman LM.
Duration of chronic inflammation alters gene expression in muscle from
untreated girls with juvenile dermatomyositis. BMC Immunol. (2008) 9:43.
doi: 10.1186/1471-2172-9-43
173. Zhao Y, Fedczyna TO,McVicker V, Caliendo J, Li H, Pachman LM. Apoptosis
in the skeletal muscle of untreated children with juvenile dermatomyositis:
impact of duration of untreated disease. Clin Immunol. (2007) 125:165–72.
doi: 10.1016/j.clim.2007.06.011
174. Lopez De Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM.
Extranodal lymphoid microstructures in inflamed muscle and disease
severity of new-onset juvenile dermatomyositis. Arthritis Rheum. (2009)
60:1160–72. doi: 10.1002/art.24411
175. Shinjo SK, Sallum AME, Silva CA, Marie SKN. Skeletal muscle major
histocompatibility complex class I and II expression differences
in adult and juvenile dermatomyositis. Clinics (2012) 67:885–90.
doi: 10.6061/clinics/2012(08)05
176. Iglesias E, Jou C, Bou R, Anton J. [Importance of muscle biopsy in
the diagnosis of juvenile dermatomyositis]. An Pediatr. (2014) 80:e25–6.
doi: 10.1016/j.anpedi.2013.04.017
177. Mamyrova G, Rider LG, Ehrlich A, Jones O, Pachman LM, Nickeson
R, et al. (2017). Environmental factors associated with disease flare
in juvenile and adult dermatomyositis. Rheumatology 56:1342–7.
doi: 10.1093/rheumatology/kex162
178. Manlhiot C, Liang L, Tran D, Bitnun A, Tyrrell PN, Feldman
BM. Assessment of an infectious disease history preceding juvenile
dermatomyositis symptom onset. Rheumatology (2008) 47:526–9.
doi: 10.1093/rheumatology/ken038
179. Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K,
Mendez EP, et al. History of infection before the onset of juvenile
dermatomyositis: results from the National Institute of Arthritis and
Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum.
(2005) 53:166–72. doi: 10.1002/art.21068
180. Pachman LM, Litt DL, Rowley AH, Hayford JR, Caliendo J, Heller S,
et al. Lack of detection of enteroviral RNA or bacterial DNA in magnetic
resonance imaging-directed muscle biopsies from twenty children with
active untreated juvenile dermatomyositis. Arthritis Rheum. (1995) 38:1513–
8. doi: 10.1002/art.1780381019
181. Jia H, Thelwell C, Dilger P, Bird C, Daniels S, Wadhwa M.
Endothelial cell functions impaired by interferon in vitro: Insights
into the molecular mechanism of thrombotic microangiopathy
associated with interferon therapy. Thromb Res. (2018) 163:105–16.
doi: 10.1016/j.thromres.2018.01.039
182. Aanhane E, Schulkens IA, Heusschen R, Castricum K, Leﬄer H, Griffioen
AW, et al. Different angioregulatory activity of monovalent galectin-9
isoforms. Angiogenesis (2018) 21:545–55. doi: 10.1007/s10456-018-9607-8
183. O’BrienMJ, Shu Q, StinsonWA, Tsou P-S, Ruth JH, Isozaki T, et al. A unique
role for galectin-9 in angiogenesis and inflammatory arthritis. Arthritis Res
Ther. (2018) 20:31. doi: 10.1186/s13075-018-1519-x
184. Heusschen R, Schulkens IA, van Beijnum J, Griffioen AW, Thijssen
VL. Endothelial LGALS9 splice variant expression in endothelial cell
biology and angiogenesis. Biochim Biophys Acta. (2014) 1842:284–92.
doi: 10.1016/j.bbadis.2013.12.003
185. Campanella GS V, Colvin RA, Luster AD. CXCL10 can inhibit endothelial
cell proliferation independently of CXCR3. PLoS ONE (2017) 5:e12700.
doi: 10.1371/journal.pone.0012700
186. Ladislau L, Suarez-Calvet X, Toquet S, Landon-Cardinal O, Amelin
D, Depp M, et al. JAK inhibitor improves type I interferon induced
damage: proof of concept in dermatomyositis. Brain (2018) 141:1609–21.
doi: 10.1093/brain/awy105
187. Crescioli C, Sottili M, Bonini P, Cosmi L, Chiarugi P, Romagnani P,
et al. Inflammatory response in human skeletal muscle cells: CXCL10
as a potential therapeutic target. Eur J Cell Biol. (2012) 91:139–49.
doi: 10.1016/j.ejcb.2011.09.011
188. Nagaraju K, Rider LG, Fan C, Chen Y-W, Mitsak M, Rawat R, et al.
Endothelial cell activation and neovascularization are prominent in
dermatomyositis. J Autoimmune Dis. (2006) 3:2. doi: 10.1186/1740-2557-3-2
189. Sorensen EW, Lian J, Ozga AJ, Miyabe Y, Ji SW, Bromley SK, et al. CXCL10
stabilizes T cell-brain endothelial cell adhesion leading to the induction of
cerebral malaria. JCI Insight (2018) 3:98911. doi: 10.1172/jci.insight.98911
190. Fu H, Kishore M, Gittens B, Wang G, Coe D, Komarowska I, et al. Self-
recognition of the endothelium enables regulatory T-cell trafficking and
defines the kinetics of immune regulation. Nat Commun. (2014) 5:3436.
doi: 10.1038/ncomms4436
191. Pober JS, Merola J, Liu R, Manes TD. Antigen presentation by vascular cells.
Front Immunol. (2017) 8:1907. doi: 10.3389/fimmu.2017.01907
192. Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco
R, et al. Consensus treatments for moderate juvenile dermatomyositis:
beyond the first two months. Results of the second Childhood Arthritis and
Rheumatology Research Alliance consensus conference. Arthritis Care Res.
(2012) 64:546–53. doi: 10.1002/acr.20695
193. McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D,
Kirkham JJ, et al. Development of a consensus core dataset in
juvenile dermatomyositis for clinical use to inform research. Ann
Rheum Dis. (2018) 77:241–50. doi: 10.1136/annrheumdis-2017-
212141
194. van Dijkhuizen, E. P., Deakin, C. T., Wedderburn, L. R., and De Iorio,
M. (2017). Modelling disease activity in juvenile dermatomyositis: a
Bayesian approach. Stat Methods Med Res. (2017). doi: 10.1177/09622802177
13233
195. Lim LSH, Pullenayegum E, Moineddin R, Gladman DD, Silverman
ED, Feldman BM. Methods for analyzing observational longitudinal
prognosis studies for rheumatic diseases: a review and worked example
using a clinic-based cohort of juvenile dermatomyositis patients.
Pediatr Rheumatol Online J. (2017) 15:18. doi: 10.1186/s12969-017-
0148-2
196. Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, et al. A
phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alphamonoclonal
antibody, shows target neutralisation of a type I IFN signature in blood of
dermatomyositis and polymyositis patients. Ann Rheum Dis. (2014) 73:256–
62. doi: 10.1136/annrheumdis-2012-202794
197. Guo X, Higgs BW, Rebelatto M, Zhu W, Greth W, Yao Y, et al.
Suppression of soluble T cell-associated proteins by an anti-interferon-
alpha monoclonal antibody in adult patients with dermatomyositis or
polymyositis. Rheumatology (2014) 53:686–695. doi: 10.1093/rheumatology/
ket413
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Wienke, Deakin, Wedderburn, van Wijk and van Royen-Kerkhof.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Immunology | www.frontiersin.org 20 December 2018 | Volume 9 | Article 2951
